CRISPR Therapeutics AG
NASDAQ:CRSP

  • LAST PRICE
    59.9900
  • TODAY'S CHANGE (%)
    2.1200 (3.6634%)
  • Bid / Lots
    59.5600/ 1
  • Ask / Lots
    60.0000/ 2
  • Open / Previous Close
    57.0000 / 57.8700
  • Day Range
    56.8000
    60.0800
  • 52 Week Range
    37.5500
    91.1000
  • Volume
    1,102,540

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
CRSP
CRISPR Therapeutics AG
5.1B
-22.2x
---
APLS
Apellis Pharmaceuticals Inc
5.0B
-12.1x
---
RARE
Ultragenyx Pharmaceutical Inc
3.4B
-5.2x
---
FOLD
Amicus Therapeutics Inc
3.1B
-20.4x
---
AXSM
Axsome Therapeutics Inc
3.5B
-11.2x
---
DNLI
Denali Therapeutics Inc
3.1B
-21.8x
---
As of 2024-06-10

Company Information

CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.

Contact Information

Headquarters
Baarerstrasse 14ZUG, ZUG, Switzerland 6300
Phone
---
Fax
---

Executives

Chairman of the Board, Chief Executive Officer
Samarth Kulkarni
Chief Financial Officer
Raju Prasad
Chief Operating Officer
Julianne Bruno
General Counsel, Secretary
James Kasinger
Chief Medical Officer
Naimish Patel

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$4.9B
Revenue (TTM)
$271.7M
Shares Outstanding
84.9M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.70
EPS
$-2.70
Book Value
$23.52
P/E Ratio
-22.2x
Price/Sales (TTM)
18.1
Price/Cash Flow (TTM)
---
Operating Margin
-109.91%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.